MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis?

Rory M. C. Abrams1 · Farinaz Safavi2 · Stanley Tuhrim1 · Allison Navis1 · Jeremy Steinberger3 · Susan C. Shin1

Received: 12 January 2021 / Revised: 16 April 2021 / Accepted: 10 May 2021 / Published online: 8 June 2021
© Journal of NeuroVirology, Inc. 2021

Abstract
Since the onset of the COVID-19 pandemic, there have been rare reports of spinal cord pathology diagnosed as inflammatory myelopathy and suspected spinal cord ischemia after SARS-CoV-2 infection. Herein, we report five cases of clinical myelopathy and myeloradiculopathy in the setting of post-COVID-19 disease, which were all radiographically negative. Unlike prior reports which typically characterized hospitalized patients with severe COVID-19 disease and critical illness, these patients typically had asymptomatic or mild-moderate COVID-19 disease and lacked radiologic evidence of structural spinal cord abnormality. This case series highlights that COVID-19 associated myelopathy is not rare, requires a high degree of clinical suspicion as imaging markers may be negative, and raises several possible pathophysiologic mechanisms.

Keywords  Inflammatory myelopathy · Ischemic myelopathy · Transverse myelopathy syndrome · Long Haul Covid · Post Acute Covid-19 Syndrome

Introduction
Since the onset of the COVID-19 pandemic, there have been increasing reports of neurologic complications including Guillain-Barré syndrome (GBS), meningitis, ischemic stroke, and CNS vasculitis associated with SARS-CoV-2 infection (Ellul et al. 2020; Guidon and Amato 2020; Abrams et al. 2020). There have also been rare reports of myelopathies and suspected spinal cord ischemia typically described in patients hospitalized for moderate-to-severe COVID-19 disease (Zachariadis et al. 2020; Zoghi et al. 2020; Sotoca and Rodríguez-Alvarez 2020; Munz et al. 2020).

However, the potential mechanisms of neurological complications following COVID-19 are not well understood. SARS-CoV-2 infection may affect the central and peripheral nervous system through the following three mechanisms: (1) systemic activation of innate immunity following moderate-to-severe infection, leading to endothelial damage and neuronal dysfunction (Quinaglia et al. 2021); (2) enhanced adaptive immunity resulting in an antibody-mediated autoimmune-inflammatory process analogous to molecular mimicry (Nath and Smith 2021); and (3) rare direct viral invasion of SARS-CoV-2 to CNS tissues inducing infectious encephalitis (Moriguchi et al. 2020).

During the first year of the pandemic, it has become increasingly apparent, that the spectrum of neurological complications can happen in patients who experienced asymptomatic or only mild COVID-19 disease (Nath 2020). Herein, we report five cases of clinical myelopathy in the setting of post-COVID-19 disease, which were all radiographically negative, which poses additional clinical obstacles to establishing a timely diagnosis. Additionally, these factors raise additional questions about mechanisms of neurological complications attributable to COVID-19.

Case series

Case 1

A 69-year-old male presented with progressive leg weakness, numbness, urinary retention, and constipation for 2 months. Examination revealed flaccid paraplegia, a T8
revealed bilateral hip flexor weakness, a T6 pinprick level, brisk patellar and Achilles reflexes, and broad-based gait. MRI C/T/L spine with contrast was unremarkable. EMG/NCS was normal. Pain improved following IV methylprednisolone, but motor and gait dysfunction persisted.

Case 5
A 63-year-old male presented with subacute onset of gait dysfunction and left leg ataxia. Examination revealed pes cavus deformities, brisk patellar and Achilles reflexes, left upgoing toes, and spastic “scissoring” gait with preserved motor strength. One month prior he experienced a viral syndrome of fever and anosmia with confirmed SARS-CoV-2 nasopharyngeal PCR. MRI C/T/L spine was unremarkable. NCS/EMG revealed mild denervation in the S1 myotomes, normal motor unit recruitment pattern but diminished activation attributed to central dysfunction. Genetic testing revealed a pathogenic mutation for autosomal dominant hereditary spastic paraplegia (HSP) 10. However, the patient adamantly denied any neurologic symptoms prior to COVID-19 disease or family history of HSP (Table 1).

Discussion
To our knowledge, this represents the largest series to date of post-COVID-19 associated myelopathy and myeloradiculopathy and uniquely identifies a phenotype affecting patients with only mild or asymptomatic SARS-CoV-2 infection. In all five cases, the patients presented with acute or subacute onset of lower extremity paresis, sensory changes, and gait dysfunction. Unlike GBS, the brisk deep tendon reflexes, spinal sensory levels, and normal distal NCS suggested upper motor neuron dysfunction which generally localized to the thoracic and lumbar cord. Unlike prior case reports which typically characterized hospitalized patients with severe COVID-19 disease, critical illness, and often radiographically apparent brain or spine signal change, this series of patients had asymptomatic or mild-moderate COVID-19 disease and lacked radiologic evidence of spinal cord abnormality. Radiologic findings in acute inflammatory myelopathies may be absent in up to 40% of cases (Scotti and Gerevini (2001)), however, the clinical severity of these myelopathies was out of proportion to either the radiologic findings or the severity of the COVID-19 disease suggesting a novel phenotype for clinicians to be aware of.

This series also highlights the prognostic challenge of predicting individuals who might develop severe neurologic complications including spinal cord dysfunction. In most of these cases, there were no significant underlying medical issues that might predispose these patients to developing myelopathy or neuropathy. Only case 5 had any indication of a pre-existing condition (HSP) which could have contributed...
| Patient | Severity of COVID illness | Time of onset from presumed viral infection to neurologic symptoms | Imaging | Serology | Spinal Fluid |
|---------|---------------------------|-----------------------------------------------------------------|---------|----------|-------------|
| Patient 1 | Asymptomatic              | Unknown but patient was hospitalized for the paraplegia during the peak COVID crisis in NYC May 2020 | MRI brain w/w/o normal (nl) MRI cervical spine w/w/o: multilevel degenerative change most prominent at C5-C6 abutting spinal cord without signal change not worsened with flexion/extension of the neck MRI thoracic nl MRI lumbar spine Degenerative anterolisthesis at L4-5 no significant neuroforaminal stenosis MRI LS plexus nl Spinal angiography × 2 nl | Positive: COVID-19 antibody 2880 (positive > 1:80) + CRP 31.63 (< 5.1 mg/L) Negative: SARS COV 2 PCR nasopharynx Antibodies to West Nile IgG, polio, VZV, HSV 1&2, Enterovirus profile, HTLV 1/II, HIV, mycoplasma, hepatitis A/B/C, Lyme, CMV NMO, MOG, paraneoplastic profile Ganglioside profile, serum immunofixation, ANA, SSA/SSB, RF, ANCA, MPO, C3/C4, anti-HU, anti-DS DNA TSH 0.7598 (0.4–4.2) Vitamin B12 996 pg/ml (211–911 pg/ml) Copper 101 (72–166 μg/dl) Vitamins E, B6, B1, zinc nl Heavy metal levels nl ESR 13 (0–13 mm/h) Fatty acid profile RPR CPK 101 U/L (30–200 U/L) ACE 18 (14–82 U/L) Hba1c 5.7 (4–6%) | RBC 1,000 (0/μl) WBC 1 (0–5 /μl) Protein 69.4 (15–45 mg/dl) Cytology, flow cytometry, immunofixation negative Corresponding viral PCRS and antibodies negative except for positive West Nile IgG antibody Corresponding autoimmune and paraneoplastic markers negative |
| Patient | Severity of COVID illness | Time of onset from presumed viral infection to neurologic symptoms | Imaging | Serology | Spinal Fluid |
|---------|---------------------------|---------------------------------------------------------------|--------|----------|-------------|
| Patient 2 | Suspected myelopathy | Mild: Loss of smell, cough, mild orthopnea for two weeks. Did not receive any treatment for the viral syndrome | Three to four months | Brain MRI w/o nl | Positive: |
|         | PMH: Hypertension, Hyperlipidemia, Prediabetes | | | MRI cervical spine w/w/o Fixed 2 mm retrolisthesis of C3 on C4 and C4 on C5 without evidence of dynamic instability. Mild spinal canal narrowing at C3-4. No cord signal change | COVID-19 antibody 960 (positive > 1:80) |
|         | | | | MRI thoracic w/w/o nl | HbA1c 6.0 (4.80–5.6%) |
|         | | | | MRI lumbar w/o mild disk bulge with facet arthropathy causing minimal central canal and mild bilateral subarticular neural foraminal narrowing | Negative: |
|         | | | | | serum B12 328 (232–1245 pg/ml) |
|         | | | | | Homocysteine 12 (<11umol/L) |
|         | | | | | Methylmalonic acid 199 (0–378 nmol/L) |
|         | | | | | TSH 2.950 (0.450–4.5) |
|         | | | | | CPK 100 (41–331 μ/L) |
|         | | | | | Vitamin E alpha 10.5 (9–29 mg/L) |
|         | | | | | Vitamin E gamma 1.5 (0.5–4.9) |
|         | | | | | ACE 40 (14–82 U/L) |
|         | | | | | Whole blood B1 107 (66–200 nmol/L) |
|         | | | | | Lyme, RPR, HTLV I/II, HIV-1/HIV-2, Copper, Zinc, Fatty acid profile, serum immunofixation, SSA/SSB, ANA |
|         | | | | | | |
| Patient 3 | Suspected myeloradiculopathy | Mild: fever, headache, anosmia, myalgias Prescribed azithromycin | Five to six months | MRI C/T/L spine nl | Positive: |
| PMH: none | | | | | COVID-19 blood IgG |
| | | | | | Negative: |
| | | | | | SARS COV 2 PCR nasopharynx |
| | | | | | Flu and respiratory panel |
| | | | | | ACE 57 (14–82 U/L) |
| | | | | | RPR, Lyme, ANA, NMO, SSA/SSB, Hepatitis B/C, HIV1&2, HTLV I/II, TSH, ESR, CRP, homocysteine, HbA1c, copper, paraneoplastic profile, ganglioside profile, serum immunofixation, West nile |
| | | | | | Vitamin B12 749 (232–1245 pg/ml) |
| | | | | | Not performed |
| Patient | Severity of COVID illness | Time of onset from presumed viral infection to neurologic symptoms | Imaging | Serology | Spinal Fluid |
|---------|---------------------------|---------------------------------------------------------------|--------|----------|-------------|
| Patient 4 | Suspected myelopathy PMH: hypertension, prediabetes | Moderate: COVID pneumonia requiring hospitalization and oxygen via nasal cannula Treated with dexamethasone, remdesivir, convalescent plasma, apixaban, and enrolled in pacritinib clinical trial | Three weeks Outpatient work up | MRI cervical and thoracic w/w/o unremarkable MRI lumbar spine w/o multi-level degenerative disk disease without significant neuroforaminal stenosis | Positive: SARS COV 2 PCR nasopharynx CRP 10.6 (0–5 MG/L) HbA1c 6.2 (4–6%) Negative: RPR, Lyme, ANA, hepatitis B/C, HIV1&2, HTLV I/II, TSH, ESR, homocysteine, copper, vitamin B1, paraneoplastic profile, ganglioside profile, serum immunofixation Vitamin B12 359 (232–1245 pg/ml) CPK 25 (25–175 U/L) | Not performed |
| Patient 5 | Suspected myelopathy PMH: denied any prior gait abnormality or family history of neurologic disease | Mild: high fever, cough, anosmia. No respiratory symptoms that required oxygen or hospitalization | Two months Outpatient work up | Brain MRI multiple intracranial cavernomas reviewed with neurosurgery, vascular neurology, neuroradiology thought not to be related to the clinical syndrome MRI C/T spine unremarkable MRI L spine Mild multilevel degenerative changes, without high-grade spinal canal stenosis. At L4-5 there is up to moderate bilateral subarticular zone stenosis | Positive: SARS COV 2 PCR nasopharynx Heterozygous mutation in KIF5A gene c.514C>T (p.Arg172Cys) which causes autosomal dominant SPG 10 Negative/normal: Lyme, HTLV I/II, whole blood thiamine, vitamin E, vitamin B12, SSA/SSB | Not performed |
to the clinical findings; this underlying genetic susceptibility may have been amplified by the preceding SARS-CoV-2 infection. However, in the other cases the preceding viral infection seems to be the sole explanation identified for the onset of a myelopathy. The specific pathophysiology in these cases remains unclear.

Other reports of inflammatory myelitis in the post-COVID-19 setting were also frequently delayed by weeks following the acute infection (Zachariadis et al. 2020; Zoghi et al. 2020; Munz et al. 2020). One hypothesis is that the evolution of IgM and IgG SARS-CoV-2 serologies may generate an autoinflammatory state (Ellul et al. 2020) or be due to a delayed T-cell response (Guidon and Amato 2020). To counter the inflammatory response, empiric treatments for inflammatory myelopathies such as steroids have been employed (Sotoca and Rodríguez-Álvarez 2020; Munz et al. 2020). Additionally, all patients herein were older than 55 years old, which is possibly indicative that aging might contribute to the development of inflammatory myelopathy with atypical radiological features due to an imbalance in immune responses (Fülöp et al. 2019).

Unfortunately, like some other authors (Zachariadis et al. 2020; Zoghi et al. 2020), our cases experienced minimal clinical recovery following standard immunotherapies like high-dose steroids. This may indicate a different etiology of the myelopathies in these patients. SARS-CoV-2 infection has been shown to cause both microhemorrhages and small vessel micro-thromboses through endothelial damage, coagulopathies, and antiphospholipid antibody-like syndrome (McFadyen et al. 2020; Salamanna et al. 2019 Jul 3; Barrantes 2021). Small vessel spinal cord strokes may explain the lack of apparent radiologic findings, lack of response to immunotherapeutic agents, and less recovery.

This case series highlights that COVID-19 associated myelopathy is less rare than previously described, particularly given the potential for subtle and delayed neurologic manifestations. COVID-19 associated myelopathy requires a high degree of clinical suspicion as imaging markers may be negative even with severe neurologic presentations. As such, this emphasizes the importance of improving prompt recognition to hopefully implement ameliorating treatments and augment recoveries, but more importantly underscores preventive public health measures which may avoid potentially life-alternating neurologic manifestations.

Acknowledgements This work was supported in part by the Intramural Research Program of the National Institute of Neurological Disorder and Stroke at National Institutes of Health.

References

Abrams RMC, Kim BD, Markantone DM, Reilly K, Paniz-Mondolfi AE, Gitman MR et al (2020) Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease. J Neurovirol 26(5):797–799

Barrantes FJ (2021) The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. Brain Behav Immun Health 14:100251

Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A et al (2020) Neurological associations of COVID-19. Lancet Neurol

Fülöp T, Larbi A, Witkowski JM (2019) Human inflammaging. Gerontology 65(5):495–504

Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology

McFadyen JD, Stevens H, Peter K (2020) The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res 127(4):571–587

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J et al (2020) A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94:55–58

Munz M, Wessendorf S, Koretis G, Tewald F, Baegi R, Krämer S et al (2020) Acute transverse myelitis after COVID-19 pneumonia. J Neurol 267(8):2196–2197

Nath A. Neurologic complications of coronavirus infections. Neurology (2020) May 12;94(19):809–810

Nath A, Smith B (2021) Neurological issues during COVID-19: An overview. Neurosci Lett Jan 18;742:135533

Quinaglia T, Shabani M, Breder I, Silber HA, Lima JAC, Sposito AC (2021) Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. Atherosclerosis 322:39–50

Salamanna F, Maglio M, Landini MP, Fini M. Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19). Platelets 2020 Jul 3;31(5):627-632

Scotti G, Gerevini S (2001) Diagnosis and differential diagnosis of acute transverse myelopathy. The role of neuroradiological investigations and review of the literature. Neurol Sci Suppl 2:S69-73

Sotoca J, Rodríguez-Álvarez Y (2020) COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm. 7(5):e803. Published 2020 Jun 10

Zachariadis A, Tulbu A, Strapu D, Dumoulin A, Di Virgilio G (2020) Transverse myelitis related to COVID-19 infection J Neurol 267(12):3459–3461

Zoghi A, Ramezani M, Rozehb M, Darazam IA, Sahraian MA (2020) A case of possible atypical demyelinating event of the central nervous system following COVID-19. Mult Scler Relat Disord 44:102324

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.